117023-22-0

Basic information

• Product Name: (1-(3-phenoxypropyl)piperidin-4-yl)diphenylmethanol
• Synonyms: (1-(3-phenoxypropyl)piperidin-4-yl)diphenylmethanol
• CAS NO: 117023-22-0
• Molecular Weight: 401.549
• Mol File: 117023-22-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (1-(3-phenoxypropyl)piperidin-4-yl)diphenylmethanol(CAS DataBase Reference)
• NIST Chemistry Reference: (1-(3-phenoxypropyl)piperidin-4-yl)diphenylmethanol(117023-22-0)
• EPA Substance Registry System: (1-(3-phenoxypropyl)piperidin-4-yl)diphenylmethanol(117023-22-0)

Safety Data

• Hazardous Substances Data: 117023-22-0(Hazardous Substances Data)

Upstream product

• 115-46-8 C₁₈H₂₁NO 
• 109-70-6 1.3-chlorobromopropane 
• 108-95-2 phenol 
• 588-63-6 3-phenoxypropyl bromide 
• 108-86-1 bromobenzene 
• 3384-04-1 3-chloropropyl phenyl ether 
• 24228-40-8 N-benzyl isonipecotic acid ethyl ester 
• 114399-88-1 α,α-diphenyl-1-(phenylmethyl)-4-piperidinemethanol 

Relevant articles and documents

High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction

The protein-protein interaction (PPI) between menin and mixed lineage leukemia (MLL) plays a critical role in acute leukemias, and inhibition of this interaction represents a new potential therapeutic strategy for MLL leukemias. We report development of a novel class of small-molecule inhibitors of the menin-MLL interaction, the hydroxy- and aminomethylpiperidine compounds, which originated from HTS of ～288000 small molecules. We determined menin-inhibitor co-crystal structures and found that these compounds closely mimic all key interactions of MLL with menin. Extensive crystallography studies combined with structure-based design were applied for optimization of these compounds, resulting in MIV-6R, which inhibits the menin-MLL interaction with IC50 = 56 nM. Treatment with MIV-6 demonstrated strong and selective effects in MLL leukemia cells, validating specific mechanism of action. Our studies provide novel and attractive scaffold as a new potential therapeutic approach for MLL leukemias and demonstrate an example of PPI amenable to inhibition by small molecules.

Synthesis and Antiallergy Activity of 4-(Diarylhydroxymethyl)-1-piperidines and Structurally Related Compounds

A series of 4-(diarylhydroxymethyl)-1-piperidines was synthesized and evaluated for antiallergy activity.Several analogues had potent activity in the passive foot anaphylaxis (PFA) assay, an IgE-mediated model useful in the detection of compounds possessing antiallergic activity.In particular 1--1-piperidinyl>propoxy>-3-methoxyphenyl>ethanone (1, AHR-5333) was more potent than oxatomide and terfenadine in this assay.